バイオマーカーの世界市場：製品・サービス別、タイプ別、研究分野別、技術別、適応疾患別、用途別、エンドユーザー別-2029年までの予測

バイオマーカーの市場規模は、予測期間中にCAGR 10.2%で拡大し、2024年の577億米ドルから2029年には938億米ドルに達すると予測されています。

同市場の成長は、これらのアッセイキットが標準化され最適化されたプロトコルを提供することで、様々な生物学的サンプル中のバイオマーカーの正確かつ効率的な分析が容易になり、ヘルスケアにおける診断や研究の取り組みに大きく貢献するという利点に起因しています。さらに、ゲノミクス、プロテオミクス、メタボロミクス、次世代シーケンシングなどの技術の進歩により、バイオマーカーの機能が拡大しています。これにより、感度、特異性、予測値が向上した新規バイオマーカーが開発されています。

2023年、世界のバイオマーカー市場では、予測バイオマーカー部門がエフィカシーバイオマーカー部門で最大のシェアを占めました。これらのバイオマーカーなどの因子は、個々の患者に合わせて治療戦略を調整するのに役立ち、潜在的な副作用を最小限に抑えながら良好な反応の可能性を最大化します。例えば、標的治療への反応を予測する遺伝子変異などがこの市場の成長を牽引しています。

アジア太平洋は、予測期間中に最も高い成長率で成長すると予想されています。高度な医療検査を受ける患者層が多いことや、がん患者に効果的な治療を提供するための政策プログラムなど、さまざまな要因がAPAC市場の高成長を後押ししています。

当レポートでは、世界のバイオマーカー市場について調査し、製品・サービス別、タイプ別、研究分野別、技術別、適応疾患別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

• イントロダクション
• 市場力学
• 顧客のビジネスに影響を与える動向/混乱
• 規制状況
• バリューチェーン分析
• 技術分析
• 価格分析
• 特許分析
• バイオマーカー市場：サプライチェーン分析
• エコシステム分析
• 2024年～2025年の主な会議とイベント
• 主な利害関係者と購入基準
• ポーターのファイブフォース分析
• 投資と資金調達のシナリオ

第6章 バイオマーカー市場、製品・サービス別

• イントロダクション
• 消耗品
• サービス
• ソフトウェア

第7章 バイオマーカー市場、タイプ別

• イントロダクション
• 安全性バイオマーカー
• 有効性バイオマーカー
• 検証バイオマーカー

第8章 バイオマーカー市場、研究分野別

• イントロダクション
• ゲノミクス
• プロテオミクス
• メタボロミクス
• その他

第9章 バイオマーカー市場、技術別

• イントロダクション
• イムノアッセイ
• 次世代シーケンシング
• PCR
• 質量分析
• クロマトグラフィ
• その他

第10章 バイオマーカー市場、適応疾患

• イントロダクション
• がん
• 感染症
• 免疫疾患
• 神経学的障害
• 心血管疾患
• その他

第11章 バイオマーカー市場、用途別

• イントロダクション
• 臨床診断
• 医薬品の発見と開発
• パーソナライズ医療
• 臨床研究
• その他

第12章 バイオマーカー市場、エンドユーザー別

• イントロダクション
• 製薬会社・バイオテクノロジー企業
• 病院・診断検査室
• 学術研究機関
• その他

第13章 バイオマーカー市場、地域別

• イントロダクション
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東
• アフリカ

第14章 競合情勢

• イントロダクション
• 主要参入企業の戦略/秘策
• 収益分析
• 市場シェア分析
• ブランド/製品比較分析
• 企業評価マトリックス：主要参入企業、2023年
• 企業評価マトリックス：スタートアップ/中小企業、2023年
• バイオマーカーベンダーの評価と財務指標
• 競合シナリオ

第15章 企業プロファイル

• 主要参入企業
  • F. HOFFMANN-LA ROCHE LTD.
  • MERCK KGAA
  • THERMO FISHER SCIENTIFIC INC.
  • QIAGEN
  • ABBOTT
  • AGILENT TECHNOLOGIES, INC.
  • REVVITY
  • CHARLES RIVER LABORATORIES
  • BIO-RAD LABORATORIES, INC.
  • EUROFINS SCIENTIFIC
  • BIOMERIEUX
  • JSR CORPORATION
  • LABORATORY CORPORATION OF AMERICA HOLDINGS
  • EKF DIAGNOSTICS
  • QUANTERIX
  • MESO SCALE DIAGNOSTICS, LLC.
• その他の企業
  • CELERION
  • STANDARD BIOTOOLS
  • SEBIA
  • BIOAGILITIX LABS
  • STRESSMARQ BIOSCIENCES INC.
  • NORTHEAST BIOANALYTICAL LABORATORIES LLC.
  • SIGNOSIS, INC.
  • SERIMMUNE
  • THERAINDX LIFESCIENCES PVT. LTD.
  • SYNEXA LIFE SCIENCES BV
  • DIATECH PHARMACOGENETICS
  • SINGULEX, INC.
  • R-BIOPHARM AG
  • PROTEOME SCIENCES

第16章 付録

The biomarkers market is expected to reach USD 93.8 billion in 2029 from USD 57.7 billion in 2024, at a CAGR of 10.2% during the forecast period.

The growth of this market can be attributed to the advantage that these assay kits offer standardized and optimized protocols, facilitating accurate and efficient analysis of biomarkers in various biological samples, thus contributing significantly to diagnostic and research endeavors in healthcare. Further, advances in technologies such as genomics, proteomics, metabolomics, and next-generation sequencing have expanded the capabilities of biomarkers. This has led to the development of novel biomarkers with enhanced sensitivity, specificity, and predictive value.

"The predictive biomarkers segment accounted for the largest share by efficacy biomarkers in 2023."

The biomarkers market by type is segmented into safety biomarkers, efficacy biomarkers, and validation biomarkers. In 2023, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers segment in the global biomarkers market. Factors such as these biomarkers help tailor treatment strategies to individual patients, maximizing the likelihood of a favorable response while minimizing potential adverse effects. Examples include genetic mutations that predict response to targeted therapies are driving the growth of this market.

"The Asia Pacific region is growing at the highest CAGR in the biomarkers market during the forecast period of 2024-2029."

The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including the large patient pool undergoing advanced medical testing and policy programs to provide effective care to cancer patients are factors driving the high growth of the APAC market.

Increased research activities from pharmaceutical and biotechnology companies to develop novel drug therapies are expected to boost the growth of the biomarkers market in the Asia Pacific region. As the region continues to invest in drug development, there is a growing demand for biomarkers supporting drug discovery efforts.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: C-level Executives - 55%, Director-level - 20%, and Others - 25%
• By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East -3%, and Africa-2%.

List of Companies Profiled in the Report:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Merck KGaA (Germany)
• Thermo Fisher Scientific Inc. (US)
• Abbott (US)
• QIAGEN (Netherlands)
• Revvity (US)
• Laboratory Corporation of America Holdings (US)
• Charles River Laboratories (US)
• Bio-Rad Laboratories, Inc. (US)
• Eurofins Scientific (Luxembourg)
• BIOMERIEUX (France)
• Agilent Technologies, Inc. (US)
• JSR Corporation (Japan)
• Quanterix (US)
• MESO SCALE DIAGNOSTICS, LLC. (US)
• EKF Diagnostics (UK)
• Celerion (US)
• Standard BioTools (US)
• Sebia (France)
• BioAgilytix Labs (US)
• StressMarq Biosciences Inc. (Canada)
• NorthEast BioAnalytical Laboratories LLC (US)
• Signosis, Inc. (US)
• Serimmune (US)
• TheraIndx Lifesciences Pvt. Ltd. (India)
• Synexa Life Sciences BV (Netherlands)
• Diatech Pharmacogenetics (Italy)
• Singulex, Inc. (US)
• R-Biopharm AG (Germany)
• Proteome Sciences (UK)

Research Coverage:

This research report categorizes the biomarkers market by product & service (consumables (assay kits, columns & filters, reagents & chemicals), services, and software), type (safety biomarkers, efficacy biomarkers (surrogate biomarkers, pharmacodynamics biomarkers, predictive biomarkers, and prognostic biomarkers), and validation biomarkers), research area (genomics, proteomics, metabolomics, and other research area), technology (immunoassays (western blot, ELISA, and protein microarray), NGS, PCR, mass spectrometry, chromatography, and other technologies), disease indication (cancer, infectious diseases, cardiovascular disorders, immunological disorders, neurological disorders, and other disease indications), application (clinical diagnostics, drug discovery & development, personalized medicines, clinical research, and other applications), end user (pharmaceutical & biotechnologies companies, hospitals & diagnostics laboratories, research & academic institutes, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report provides in-depth information on significant factors influencing the growth of the biomarkers market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, and acquisitions within the biomarkers market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing significance of biomarkers in drug discovery and development, Growing importance of companion diagnostics, Increase in global prevalence of cancer, Growing importance of biomarkers for rare conditions, Increase in funds and grants for biomarker research, Advancement in omics technologies and continuous product innovations), restraints (High capital investments and lengthy timelines for biomarker development, Disease complexity, and heterogeneity), opportunities (Shift towards personalized medicine and precision oncology, Enhanced collaboration among healthcare providers and key industry players, Emerging economies), and challenges (Challenges associated with quantification and validation of biomarkers, Challenges associated integration of complex data sets, Technical issues related to sample collection and storage) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products/services of the biomarkers market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the biomarkers market
• Competitive Assessment: F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMERIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), Quanterix (US), MESO SCALE DIAGNOSTICS, LLC. (US), EKF Diagnostics (UK), Celerion (US), Standard BioTools (US), Sebia (France), BioAgilytix Labs (US), StressMarq Biosciences Inc. (Canada), NorthEast BioAnalytical Laboratories LLC (US), Signosis, Inc. (US), Serimmune (US), TheraIndx Lifesciences Pvt. Ltd. (India), Synexa Life Sciences BV (Netherlands), Diatech Pharmacogenetics (Italy), Singulex, Inc. (US), R-Biopharm AG (Germany), and Proteome Sciences (UK) among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 REGIONS COVERED
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES
  • 1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • FIGURE 1 RESEARCH DESIGN
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
  • FIGURE 2 BREAKDOWN OF PRIMARIES: BIOMARKERS MARKET
• 2.2 MARKET ESTIMATION METHODOLOGY
  • FIGURE 3 BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • 2.2.1 GLOBAL MARKET ESTIMATION
  • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
  • FIGURE 5 ILLUSTRATIVE EXAMPLE OF HOFFMANN-LA ROCHE LTD.: REVENUE SHARE ANALYSIS (2023)
    • 2.2.1.1 Insights of primary experts
  • FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
  • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTIONS
  • FIGURE 8 BIOMARKERS MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
  • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • FIGURE 9 DATA TRIANGULATION METHODOLOGY
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 LIMITATIONS
• 2.7 RISK ANALYSIS
• 2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

• FIGURE 10 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
• FIGURE 11 BIOMARKERS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
• FIGURE 12 BIOMARKERS MARKET, BY RESEARCH AREA, 2024 VS. 2029 (USD MILLION)
• FIGURE 13 BIOMARKERS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
• FIGURE 14 BIOMARKERS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 15 GEOGRAPHICAL SNAPSHOT OF BIOMARKERS MARKET

4 PREMIUM INSIGHTS

• 4.1 BIOMARKERS MARKET OVERVIEW
  • FIGURE 16 ADVANCEMENTS IN OMICS TECHNOLOGIES AND RISING DRUG DISCOVERY & DEVELOPMENT ACTIVITIES TO PROPEL MARKET
• 4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE
  • FIGURE 17 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
• 4.3 BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 18 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
• 4.4 BIOMARKERS MARKET SHARE, BY END USER (2023)
  • FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 20 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • TABLE 2 BIOMARKERS MARKET: IMPACT ANALYSIS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing use of biomarkers in drug discovery & development
    • 5.2.1.2 Growing importance of companion diagnostics
    • 5.2.1.3 Rising prevalence of cancer
  • TABLE 3 CANCER INCIDENCE, BY REGION (2040)
    • 5.2.1.4 Increasing development of biomarkers for rare diseases
    • 5.2.1.5 Increasing funds and grants for biomarker research
    • 5.2.1.6 Advancements in omics technologies
  • TABLE 4 PRODUCT APPROVALS & LAUNCHES (2022-2024)
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High capital investment and extensive timelines for biomarker development
  • TABLE 5 TIME FRAME FOR BIOMARKER DEVELOPMENT
    • 5.2.2.2 Disease complexity and heterogeneity
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing preference for personalized medicine and precision oncology
    • 5.2.3.2 Technological innovations between healthcare providers and key industry players
    • 5.2.3.3 High growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Issues associated with quantification & validation of biomarkers
    • 5.2.4.2 Complexities associated with data set integration
    • 5.2.4.3 Technical issues related to sample collection and storage
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 21 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 REGULATORY LANDSCAPE
  • 5.4.1 US
  • 5.4.2 EUROPE
  • 5.4.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.5 VALUE CHAIN ANALYSIS
  • FIGURE 22 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
• 5.6 TECHNOLOGICAL ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 Immunoassays
      • 5.6.1.1.1 Immunohistochemistry (IHC)
      • 5.6.1.1.2 ELISA
    • 5.6.1.2 Next-generation Sequencing (NGS)
    • 5.6.1.3 Polymerase Chain Reaction (PCR)
    • 5.6.1.4 In Situ Hybridization
    • 5.6.1.5 Microarrays
    • 5.6.1.6 Mass Spectrometry
  • 5.6.2 COMPLIMENTARY TECHNOLOGIES
    • 5.6.2.1 Liquid Biopsy
    • 5.6.2.2 CRISPR
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Artificial Intelligence (AI) and Machine Learning (ML)
    • 5.6.3.2 Sensors (Wearable Devices)
• 5.7 PRICING ANALYSIS
  • 5.7.1 AVERAGE SELLING PRICE OF BIOMARKERS CONSUMABLES
  • TABLE 10 AVERAGE SELLING PRICE OF BIOMARKERS BY KEY PLAYERS
  • 5.7.2 AVERAGE SELLING PRICE OF BIOMARKERS CONSUMABLES
  • TABLE 11 AVERAGE SELLING PRICE OF BIOMARKERS BY REGION
• 5.8 PATENT ANALYSIS
  • 5.8.1 METHODOLOGY
  • 5.8.2 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
  • TABLE 12 PATENTS FILED, 2014-2024
  • 5.8.3 INNOVATION AND PATENT APPLICATIONS
  • FIGURE 23 NUMBER OF PATENTS GRANTED IN THE PAST 10 YEARS
  • 5.8.4 TOP APPLICANTS
  • FIGURE 24 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2024
  • TABLE 13 TOP 20 PATENT OWNERS IN BIOMARKERS, 2014-2024
  • TABLE 14 INDICATIVE LIST OF PATENTS IN BIOMARKERS MARKET, 2022-2024
• 5.9 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 25 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
• 5.10 ECOSYSTEM ANALYSIS
  • FIGURE 26 BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
  • 5.10.1 BIOMARKER TESTING RAW MATERIAL SUPPLIERS
  • TABLE 15 BIOMARKERS MARKET: RAW MATERIAL SUPPLIERS
  • 5.10.2 BIOMARKER TESTING PRODUCT VENDORS
  • TABLE 16 BIOMARKERS MARKET: PRODUCT VENDORS
  • 5.10.3 BIOMARKER TESTING SERVICE PROVIDERS
  • TABLE 17 BIOMARKERS MARKET: SERVICE PROVIDERS
  • 5.10.4 BIOMARKER TESTING END USERS
  • TABLE 18 BIOMARKERS MARKET: END USERS
  • 5.10.5 BIOMARKER TESTING REGULATORY AUTHORITIES
  • TABLE 19 BIOMARKERS MARKET: REGULATORY AUTHORITIES
• 5.11 KEY CONFERENCES AND EVENTS, 2024-2025
  • TABLE 20 BIOMARKERS MARKET: LIST OF CONFERENCES AND EVENTS
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF BIOMARKERS
  • 5.12.2 BIOMARKERS MARKET: BUYING CRITERIA
  • FIGURE 28 KEY BUYING CRITERIA FOR END USERS
  • TABLE 21 BUYING CRITERIA FOR BIOMARKER PRODUCTS, BY END USER
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 22 IMPACT OF PORTER'S FIVE FORCES ON BIOMARKERS MARKET
  • 5.13.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.13.2 BARGAINING POWER OF SUPPLIERS
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 THREAT OF SUBSTITUTES
  • 5.13.5 THREAT OF NEW ENTRANTS
• 5.14 INVESTMENT AND FUNDING SCENARIO
  • TABLE 23 US: CANCER BIOMARKER FUNDING, 2021-2024

6 BIOMARKERS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
  • TABLE 24 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
• 6.2 CONSUMABLES
  • TABLE 25 CONSUMABLES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 26 NORTH AMERICA: CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 27 EUROPE: CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 LATIN AMERICA: CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 MIDDLE EAST: CONSUMABLES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 31 GCC COUNTRIES: CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 32 CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 6.2.1 ASSAY KITS
    • 6.2.1.1 Usage in biomolecule detection, quantification, and characterization to boost demand
  • TABLE 33 ASSAY KITS MARKETS, BY REGION, 2022-2029 USD MILLION)
  • TABLE 34 NORTH AMERICA: ASSAY KITS MARKETS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 EUROPE: ASSAY KITS MARKETS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: ASSAY KITS MARKETS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 LATIN AMERICA: ASSAY KITS MARKETS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 MIDDLE EAST: ASSAY KITS MARKETS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 39 GCC COUNTRIES: ASSAY KITS MARKETS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.2.2 REAGENTS & CHEMICALS
    • 6.2.2.1 Recurrent usage in drug discovery & development to boost demand
  • TABLE 40 REAGENTS & CHEMICALS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 41 NORTH AMERICA: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 EUROPE: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 LATIN AMERICA: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 MIDDLE EAST: REAGENTS & CHEMICALS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 46 GCC COUNTRIES: REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.2.3 COLUMNS & FILTERS
    • 6.2.3.1 High uptake across end-user facilities to support market growth
  • TABLE 47 COLUMNS & FILTERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 48 NORTH AMERICA: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 EUROPE: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 LATIN AMERICA: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 MIDDLE EAST: COLUMNS & FILTERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 53 GCC COUNTRIES: COLUMNS & FILTERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• 6.3 SERVICES
  • 6.3.1 INCREASING NUMBER OF CROS TO DRIVE MARKET
  • TABLE 54 BIOMARKER SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 55 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 LATIN AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 MIDDLE EAST: BIOMARKER SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 60 GCC COUNTRIES: BIOMARKER SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• 6.4 SOFTWARE
  • 6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET
  • TABLE 61 SOFTWARE MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 62 NORTH AMERICA: SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 EUROPE: SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 65 LATIN AMERICA: SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 MIDDLE EAST: SOFTWARE MARKET, BY REGION,2022-2029 (USD MILLION)
  • TABLE 67 GCC COUNTRIES: SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

7 BIOMARKERS MARKET, BY TYPE

• 7.1 INTRODUCTION
  • TABLE 68 BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
• 7.2 SAFETY BIOMARKERS
  • 7.2.1 ABILITY TO MEASURE ADVERSE EFFECTS TO PROPEL MARKET
  • TABLE 69 SAFETY BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 70 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 LATIN AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 MIDDLE EAST: SAFETY BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 75 GCC COUNTRIES: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• 7.3 EFFICACY BIOMARKERS
  • TABLE 76 EFFICACY BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 77 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 78 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 82 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 7.3.1 PREDICTIVE BIOMARKERS
    • 7.3.1.1 Ease of patient identification to support market growth
  • TABLE 84 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 85 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 86 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 LATIN AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 89 MIDDLE EAST: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 90 GCC COUNTRIES: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.3.2 SURROGATE BIOMARKERS
    • 7.3.2.1 Ease of tracking treatment effectiveness to drive adoption
  • TABLE 91 SURROGATE BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 93 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 95 LATIN AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 96 MIDDLE EAST: SURROGATE BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 97 GCC COUNTRIES: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.3.3 PHARMACODYNAMIC BIOMARKERS
    • 7.3.3.1 High uptake in selection and optimization of drug doses to drive market
  • TABLE 98 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 99 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 100 EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 102 LATIN AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 103 MIDDLE EAST: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 104 GCC COUNTRIES: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.3.4 PROGNOSTIC BIOMARKERS
    • 7.3.4.1 Ability to predict health outcomes without therapeutic intervention to propel adoption
  • TABLE 105 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 106 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 107 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 109 LATIN AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 110 MIDDLE EAST: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 111 GCC COUNTRIES: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• 7.4 VALIDATION BIOMARKERS
  • 7.4.1 INCREASING ADOPTION BY REGULATORY AGENCIES FOR THERAPEUTIC COMMERCIALIZATION TO DRIVE MARKET
  • TABLE 112 VALIDATION BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 113 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 114 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 116 LATIN AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 117 MIDDLE EAST: VALIDATION BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 118 GCC COUNTRIES: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

8 BIOMARKERS MARKET, BY RESEARCH AREA

• 8.1 INTRODUCTION
  • TABLE 119 BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
• 8.2 GENOMICS
  • 8.2.1 RISING TECHNOLOGICAL ADVANCEMENTS FOR BIOMARKER TESTING TO PROPEL MARKET
  • TABLE 120 BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 121 NORTH AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 122 EUROPE: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 124 LATIN AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 125 MIDDLE EAST: BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 126 GCC COUNTRIES: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
• 8.3 PROTEOMICS
  • 8.3.1 RISING INCIDENCE OF CHRONIC DISEASES TO BOOST DEMAND
  • TABLE 127 BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 128 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 129 EUROPE: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 131 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 132 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 133 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
• 8.4 METABOLOMICS
  • 8.4.1 RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH
  • TABLE 134 BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 135 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 136 EUROPE: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 137 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 138 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 139 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 140 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
• 8.5 OTHER RESEARCH AREAS
  • TABLE 141 BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 142 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 143 EUROPE: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 145 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 146 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 147 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2022-2029 (USD MILLION)

9 BIOMARKERS MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
  • TABLE 148 BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
• 9.2 IMMUNOASSAYS
  • TABLE 149 IMMUNOASSAYS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 150 IMMUNOASSAYS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 151 NORTH AMERICA: IMMUNOASSAYS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 152 EUROPE: IMMUNOASSAYS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: IMMUNOASSAYS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 154 LATIN AMERICA: IMMUNOASSAYS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 155 MIDDLE EAST: IMMUNOASSAYS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 156 GCC COUNTRIES: IMMUNOASSAYS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.2.1 ELISA
    • 9.2.1.1 ELISA to hold largest market share
  • TABLE 157 ELISA MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 158 NORTH AMERICA: ELISA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 159 EUROPE: ELISA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: ELISA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 161 LATIN AMERICA: ELISA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 162 MIDDLE EAST: ELISA MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 163 GCC COUNTRIES: ELISA MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.2.2 PROTEIN MICROARRAYS
    • 9.2.2.1 Cost efficIency and high sensitivity to propel adoption
  • TABLE 164 PROTEIN MICROARRAYS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 165 NORTH AMERICA: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 166 EUROPE: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 168 LATIN AMERICA: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 169 MIDDLE EAST: PROTEIN MICROARRAYS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 170 GCC COUNTRIES: PROTEIN MICROARRAYS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.2.3 WESTERN BLOT
    • 9.2.3.1 Increasing utilization in translation medicine to drive market
  • TABLE 171 WESTERN BLOT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 172 NORTH AMERICA: WESTERN BLOT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 173 EUROPE: WESTERN BLOT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 174 ASIA PACIFIC: WESTERN BLOT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 175 LATIN AMERICA: WESTERN BLOT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 176 MIDDLE EAST: WESTERN BLOT MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 177 GCC COUNTRIES: WESTERN BLOT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• 9.3 NGS
  • 9.3.1 TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO BOOST DEMAND
  • TABLE 178 NGS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 179 NORTH AMERICA: NGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 180 EUROPE: NGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: NGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 182 LATIN AMERICA: NGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 183 MIDDLE EAST: NGS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 184 GCC COUNTRIES: NGS MARKET, 2022-2029 (USD MILLION)
• 9.4 PCR
  • 9.4.1 RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET
  • TABLE 185 PCR MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 186 NORTH AMERICA: PCR MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 187 EUROPE: PCR MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: PCR MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 189 LATIN AMERICA: PCR MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 190 MIDDLE EAST: PCR MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 191 GCC COUNTRIES: PCR MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• 9.5 MASS SPECTROMETRY
  • 9.5.1 INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE MARKET
  • TABLE 192 MASS SPECTROMETRY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 193 NORTH AMERICA: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 194 EUROPE: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 195 ASIA PACIFIC: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 196 LATIN AMERICA: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 197 MIDDLE EAST: MASS SPECTROMETRY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 198 GCC COUNTRIES: MASS SPECTROMETRY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• 9.6 CHROMATOGRAPHY
  • 9.6.1 UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH
  • TABLE 199 CHROMATOGRAPHY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 200 NORTH AMERICA: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 201 EUROPE: CHROMATOGRAPHY MARKET, BY COUNTRY,2022-2029 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 203 LATIN AMERICA: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 204 MIDDLE EAST: CHROMATOGRAPHY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 205 GCC COUNTRIES: CHROMATOGRAPHY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• 9.7 OTHER TECHNOLOGIES
  • TABLE 206 OTHER TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 207 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 208 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 210 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 211 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 212 GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

10 BIOMARKERS MARKET, BY DISEASE INDICATION

• 10.1 INTRODUCTION
  • TABLE 213 BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
• 10.2 CANCER
  • 10.2.1 RISING INCIDENCE OF CANCER AND GROWING FOCUS ON EARLY DISEASE DETECTION TO PROPEL MARKET
  • TABLE 214 LIST OF FDA-APPROVED BIOMARKERS FOR CANCER, BY TYPE
  • TABLE 215 BIOMARKERS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 216 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 217 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 219 LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 220 MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 221 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
• 10.3 INFECTIOUS DISEASES
  • 10.3.1 INCREASING INCIDENCE OF HIV AND TB TO BOOST DEMAND
  • TABLE 222 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 223 NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 224 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 226 LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 227 MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 228 GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• 10.4 IMMUNOLOGICAL DISORDERS
  • 10.4.1 RISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET
  • TABLE 229 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
  • TABLE 230 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 231 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 232 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 234 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 235 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 236 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• 10.5 NEUROLOGICAL DISORDERS
  • 10.5.1 HIGH UPTAKE OF ELISA FOR DIAGNOSIS TO SUPPORT MARKET GROWTH
  • TABLE 237 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 238 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 239 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 240 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 241 LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 242 MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 243 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY NEUROLOGICAL DISORDERS, 2022-2029 (USD MILLION)
• 10.6 CARDIOVASCULAR DISORDERS
  • 10.6.1 TECHNOLOGICAL ADVANCEMENTS IN CARDIAC BIOMARKERS TO BOOST DEMAND
  • TABLE 244 BIOMARKERS FOR CARDIOVASCULAR DISORDERS
  • TABLE 245 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 246 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 247 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 248 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 249 LATIN AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 250 MIDDLE EAST: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 251 GCC COUNTRIES: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• 10.7 OTHER DISEASE INDICATIONS
  • TABLE 252 BIOMARKERS FOR RENAL DISORDERS
  • TABLE 253 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 254 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 255 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 256 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 257 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 258 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 259 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)

11 BIOMARKERS MARKET, BY APPLICATION

• 11.1 INTRODUCTION
  • TABLE 260 BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• 11.2 CLINICAL DIAGNOSTICS
  • 11.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO BOOST DEMAND
  • TABLE 261 BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 262 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 263 EUROPE: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 264 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 265 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 266 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 267 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
• 11.3 DRUG DISCOVERY & DEVELOPMENT
  • 11.3.1 RISING FOCUS ON COST REDUCTION AND TREATMENT EFFICACY TO PROPEL MARKET
  • TABLE 268 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 269 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 270 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 271 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 272 LATIN AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 273 MIDDLE EAST: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 274 GCC COUNTRIES: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022-2029 (USD MILLION)
• 11.4 PERSONALIZED MEDICINE
  • 11.4.1 GROWING PREFERENCE FOR THERAPEUTICS TO DRIVE MARKET
  • TABLE 275 LIST OF KEY PERSONALIZED MEDICINES AND RELEVANT BIOMARKERS
  • TABLE 276 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 277 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 278 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 279 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 280 LATIN AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 281 MIDDLE EAST: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 282 GCC COUNTRIES: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022-2029 (USD MILLION)
• 11.5 CLINICAL RESEARCH
  • 11.5.1 INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH
  • TABLE 283 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION
  • TABLE 284 BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 285 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 286 EUROPE: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 287 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 288 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 289 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 290 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2022-2029 (USD MILLION)
• 11.6 OTHER APPLICATIONS
  • TABLE 291 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 292 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 293 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 294 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 295 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 296 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 297 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)

12 BIOMARKERS MARKET, BY END USER

• 12.1 INTRODUCTION
  • TABLE 298 BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
• 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 12.2.1 RISING DRUG DISCOVERY ACTIVITIES FOR NOVEL BIOMARKERS TO PROPEL MARKET
  • TABLE 299 PHARMA & BIOTECH SECTOR: RECENT DEVELOPMENTS
  • TABLE 300 BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 301 NORTH AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 302 EUROPE: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 303 ASIA PACIFIC: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 304 LATIN AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 305 MIDDLE EAST: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 306 GCC COUNTRIES: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• 12.3 HOSPITALS & DIAGNOSTIC LABORATORIES
  • 12.3.1 UPTAKE OF IMAGING BIOMARKERS IN CLINICAL SETTINGS TO BOOST DEMAND
  • TABLE 307 BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 308 NORTH AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 309 EUROPE: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 310 ASIA PACIFIC: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 311 LATIN AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 312 MIDDLE EAST: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 313 GCC COUNTRIES: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
• 12.4 ACADEMIC & RESEARCH INSTITUTES
  • 12.4.1 RISING FOCUS ON STEM CELL AND CANCER RESEARCH TO SUPPORT MARKET GROWTH
  • TABLE 314 BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 315 NORTH AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 316 EUROPE: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 317 ASIA PACIFIC: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 318 LATIN AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 319 MIDDLE EAST: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 320 GCC COUNTRIES: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• 12.5 OTHER END USERS
  • TABLE 321 BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 322 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 323 EUROPE: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 324 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 325 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 326 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 327 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)

13 BIOMARKERS MARKET, BY REGION

• 13.1 INTRODUCTION
  • TABLE 328 BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
• 13.2 NORTH AMERICA
  • 13.2.1 NORTH AMERICA: RECESSION IMPACT
  • FIGURE 29 NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT
  • TABLE 329 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 330 NORTH AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 331 NORTH AMERICA: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 332 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 333 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 334 NORTH AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 335 NORTH AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 336 NORTH AMERICA: IMMUNOASSAYS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 337 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 338 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 339 NORTH AMERICA: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.2.2 US
    • 13.2.2.1 Rising focus on biopharma research to propel market
  • FIGURE 30 NIH FUNDING MEDICAL RESEARCH IN 10 YEARS (2014-2024)
  • TABLE 340 US: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 341 US: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 342 US: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 343 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 344 US: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 345 US: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 USD MILLION)
  • TABLE 346 US: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 347 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 348 US: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 349 US: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.2.3 CANADA
    • 13.2.3.1 Increasing incidence of cancer to boost demand for biomarker discovery
  • TABLE 350 CANADA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 351 CANADA: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 352 CANADA: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 353 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 354 CANADA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 355 CANADA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 356 CANADA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 357 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 358 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 359 CANADA: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
• 13.3 EUROPE
  • 13.3.1 EUROPE: RECESSION IMPACT
  • TABLE 360 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 361 EUROPE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 362 EUROPE: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 363 EUROPE: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 364 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 365 EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 366 EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 367 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 368 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 369 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 370 EUROPE: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.3.2 GERMANY
    • 13.3.2.1 Growth in biopharmaceutical R&D activities to propel market
  • TABLE 371 GERMANY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 372 GERMANY: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 373 GERMANY: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 374 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 375 GERMANY: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 376 GERMANY: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 377 GERMANY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 378 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 379 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 380 GERMANY: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.3.3 UK
    • 13.3.3.1 Government funding and strategic collaborations with biotech firms to drive market
  • TABLE 381 UK: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 382 UK: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 383 UK: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 384 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 385 UK: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 386 UK: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 387 UK: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 388 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 389 UK: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 390 UK: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.3.4 FRANCE
    • 13.3.4.1 Rising funding for proteomics & genomics research to drive market
  • TABLE 391 FRANCE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 392 FRANCE: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 393 FRANCE: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 394 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 395 FRANCE: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 396 FRANCE: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 397 FRANCE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 398 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 399 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 400 FRANCE: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.3.5 ITALY
    • 13.3.5.1 Increasing developments in life sciences research to fuel market
  • TABLE 401 ITALY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 402 ITALY: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 403 ITALY: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 404 ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 405 ITALY: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 406 ITALY: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 407 ITALY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 408 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 409 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 410 ITALY: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.3.6 SPAIN
    • 13.3.6.1 R&D initiatives for personalized medicine to support market growth
  • TABLE 411 SPAIN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 412 SPAIN: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 413 SPAIN: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 414 SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 415 SPAIN: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 416 SPAIN: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 417 SPAIN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 418 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 419 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 420 SPAIN: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.3.7 REST OF EUROPE
  • TABLE 421 REST OF EUROPE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 422 REST OF EUROPE: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 423 REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 424 REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 425 REST OF EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 426 REST OF EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 427 REST OF EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 428 REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 429 REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 430 REST OF EUROPE: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
• 13.4 ASIA PACIFIC
  • 13.4.1 ASIA PACIFIC: RECESSION IMPACT
  • FIGURE 31 ASIA PACIFIC: BIOMARKERS MARKET SNAPSHOT
  • TABLE 431 ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 432 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 433 ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 434 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 435 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 436 ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 437 ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 438 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 439 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 440 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 441 ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.4.2 CHINA
    • 13.4.2.1 Rising incidence of CVD to propel market
  • TABLE 442 CHINA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 443 CHINA: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 444 CHINA: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 445 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 446 CHINA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 447 CHINA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 448 CHINA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 449 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 450 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 451 CHINA: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.4.3 JAPAN
    • 13.4.3.1 Stringent regulatory guidelines for drug discovery & development to propel market
  • TABLE 452 JAPAN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 453 JAPAN: CONSUMABLES MARKET, BY TYPE, 022-2029 (USD MILLION)
  • TABLE 454 JAPAN: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 455 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 456 JAPAN: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 457 JAPAN: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 458 JAPAN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 459 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 460 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 461 JAPAN: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.4.4 INDIA
    • 13.4.4.1 Favorable scenario for FDIs and increasing number of clinical trials to propel market
  • TABLE 462 INDIA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 463 INDIA: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 464 INDIA: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 465 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 466 INDIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 467 INDIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 468 INDIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 469 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 470 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 471 INDIA: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.4.5 SOUTH KOREA
    • 13.4.5.1 Increasing innovations in NGS platforms to boost demand
  • TABLE 472 SOUTH KOREA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 473 SOUTH KOREA: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 474 SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 475 SOUTH KOREA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 476 SOUTH KOREA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 477 SOUTH KOREA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 478 SOUTH KOREA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 479 SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 480 SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 481 SOUTH KOREA: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.4.6 AUSTRALIA
    • 13.4.6.1 Growing demand for diagnostic solutions to support market growth
  • TABLE 482 AUSTRALIA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 483 AUSTRALIA: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 484 AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 485 AUSTRALIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 486 AUSTRALIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 487 AUSTRALIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 488 AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 489 AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 490 AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 491 AUSTRALIA: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.4.7 REST OF ASIA PACIFIC
  • TABLE 492 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 493 REST OF ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 494 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 495 REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 496 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 497 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 498 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 499 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 500 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 501 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)

• 13.5 LATIN AMERICA
  • 13.5.1 LATIN AMERICA: RECESSION IMPACT
  • TABLE 502 LATIN AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 503 LATIN AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 504 LATIN AMERICA: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 505 LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 506 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 507 LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 508 LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 509 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 510 LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 511 LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 512 LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.5.2 BRAZIL
    • 13.5.2.1 Increased government investments in pharmaceutical R&D to drive market
  • TABLE 513 BRAZIL: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 514 BRAZIL: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 515 BRAZIL: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 516 BRAZIL: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 517 BRAZIL: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 518 BRAZIL: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 519 BRAZIL: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 520 BRAZIL: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 521 BRAZIL: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 522 BRAZIL: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.5.3 MEXICO
    • 13.5.3.1 Rising demand for advanced healthcare services to support market growth
  • TABLE 523 MEXICO: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 524 MEXICO: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 525 MEXICO: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 526 MEXICO: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 527 MEXICO: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 528 MEXICO: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 529 MEXICO: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 530 MEXICO: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 531 MEXICO: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 532 MEXICO: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.5.4 REST OF LATIN AMERICA
  • TABLE 533 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 534 REST OF LATIN AMERICA: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 535 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 536 REST OF LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 537 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 538 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 539 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 540 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 541 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 542 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
• 13.6 MIDDLE EAST
  • 13.6.1 MIDDLE EAST: RECESSION IMPACT
  • TABLE 543 MIDDLE EAST: BIOMARKERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 544 MIDDLE EAST: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 545 MIDDLE EAST: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 546 MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 547 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 548 MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 549 MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 550 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 551 MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 552 MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 553 MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.6.2 GCC COUNTRIES
  • TABLE 554 GCC COUNTRIES: BIOMARKERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 555 GCC COUNTRIES: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 556 GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 557 GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 558 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 559 GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 560 GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 561 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 562 GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 563 GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 564 GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.6.2.1 Kingdom of Saudi Arabia
      • 13.6.2.1.1 Growth in healthcare expenditure to boost demand
  • TABLE 565 KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 566 KINGDOM OF SAUDI ARABIA: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 567 KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 568 KINGDOM OF SAUDI ARABIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 569 KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 570 KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 571 KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 572 KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 573 KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 574 KINGDOM OF SAUDI ARABIA: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.6.2.2 United Arab Emirates
      • 13.6.2.2.1 Increasing collaborative efforts for pharmaceutical R&D to drive market
  • TABLE 575 UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 576 UNITED ARAB EMIRATES: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 577 UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 578 UNITED ARAB EMIRATES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 579 UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 580 UNITED ARAB EMIRATES: BIOMARKERS MARKET BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 581 UNITED ARAB EMIRATES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 582 UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 583 UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 584 UNITED ARAB EMIRATES: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 13.6.2.3 Other GCC Countries
  • TABLE 585 OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 586 OTHER GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 587 OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 588 OTHER GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 589 OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 590 OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 591 OTHER GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 592 OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 593 OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 594 OTHER GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.6.3 REST OF MIDDLE EAST
  • TABLE 595 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 596 REST OF MIDDLE EAST: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 597 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 598 REST OF MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 599 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 600 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 601 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 602 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 603 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 604 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
• 13.7 AFRICA
  • 13.7.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH
  • TABLE 605 AFRICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 606 AFRICA: CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 607 AFRICA: BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 608 AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 609 AFRICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2022-2029 (USD MILLION)
  • TABLE 610 AFRICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 611 AFRICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 612 AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • TABLE 613 AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 614 AFRICA: BIOMARKERS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 13.7.2 AFRICA: RECESSION IMPACT

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • TABLE 615 OVERVIEW OF STRATEGIES DEPLOYED BY KEY BIOMARKER COMPANIES
• 14.3 REVENUE ANALYSIS
  • FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS, 2019-2023 (USD BILLION)
• 14.4 MARKET SHARE ANALYSIS
  • FIGURE 33 BIOMARKERS MARKET SHARE ANALYSIS, BY KEY PLAYER (2023)
  • TABLE 616 BIOMARKERS MARKET: DEGREE OF COMPETITION
• 14.5 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 34 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT & SERVICE
• 14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 14.6.1 STARS
  • 14.6.2 EMERGING LEADERS
  • 14.6.3 PERVASIVE PLAYERS
  • 14.6.4 PARTICIPANTS
  • FIGURE 35 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • 14.6.5 COMPANY FOOTPRINT ANALYSIS (KEY PLAYERS), 2023
  • FIGURE 36 BIOMARKERS MARKET: COMPANY FOOTPRINT
  • TABLE 617 BIOMARKERS MARKET: REGIONAL FOOTPRINT
  • TABLE 618 BIOMARKERS MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 619 BIOMARKERS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 620 BIOMARKERS MARKET: APPLICATION FOOTPRINT
• 14.7 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
  • 14.7.1 PROGRESSIVE COMPANIES
  • 14.7.2 RESPONSIVE COMPANIES
  • 14.7.3 DYNAMIC COMPANIES
  • 14.7.4 STARTING BLOCKS
  • FIGURE 37 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
  • 14.7.5 COMPETITIVE BENCHMARKING
  • TABLE 621 BIOMARKERS MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 622 BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
• 14.8 VALUATION AND FINANCIAL METRICS OF BIOMARKER VENDORS
  • FIGURE 38 EV/EBITDA OF KEY VENDORS
  • FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • TABLE 623 BIOMARKERS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2024
  • 14.9.2 DEALS
  • TABLE 624 BIOMARKERS MARKET: DEALS, JANUARY 2021-APRIL 2024
  • 14.9.3 EXPANSIONS
  • TABLE 625 BIOMARKERS MARKET: EXPANSIONS, JANUARY 2021-APRIL 2024

15 COMPANY PROFILES

• (Business Overview, Products/Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
• 15.1 KEY PLAYERS
  • 15.1.1 F. HOFFMANN-LA ROCHE LTD.
  • TABLE 626 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • TABLE 627 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 628 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS
  • TABLE 629 F. HOFFMANN-LA ROCHE LTD.: DEALS
  • 15.1.2 MERCK KGAA
  • TABLE 630 MERCK KGAA: COMPANY OVERVIEW
  • FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2023)
  • TABLE 631 MERCK KGAA: PRODUCTS/SERVICES OFFERED
  • TABLE 632 MERCK KGAA: DEALS
  • TABLE 633 MERCK KGAA: EXPANSIONS
  • 15.1.3 THERMO FISHER SCIENTIFIC INC.
  • TABLE 634 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • TABLE 635 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 636 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 637 THERMO FISHER SCIENTIFIC INC.: DEALS
  • TABLE 638 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
  • 15.1.4 QIAGEN
  • TABLE 639 QIAGEN: COMPANY OVERVIEW
  • FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2023)
  • TABLE 640 QIAGEN: PRODUCTS/SERVICES OFFERED
  • TABLE 641 QIAGEN: PRODUCT/SERVICE APPROVALS
  • TABLE 642 QIAGEN: DEALS
  • 15.1.5 ABBOTT
  • TABLE 643 ABBOTT: COMPANY OVERVIEW
  • FIGURE 44 ABBOTT: COMPANY SNAPSHOT (2023)
  • TABLE 644 ABBOTT: PRODUCTS/SERVICES OFFERED
  • TABLE 645 ABBOTT: PRODUCT/SERVICE APPROVALS
  • TABLE 646 ABBOTT: DEALS
  • 15.1.6 AGILENT TECHNOLOGIES, INC.
  • TABLE 647 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • FIGURE 45 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
  • TABLE 648 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 649 AGILENT TECHNOLOGIES, INC.: PRODUCT/SERVICE APPROVALS
  • TABLE 650 AGILENT TECHNOLOGIES, INC.: DEALS
  • 15.1.7 REVVITY
  • TABLE 651 REVVITY: COMPANY OVERVIEW
  • FIGURE 46 REVVITY: COMPANY SNAPSHOT (2023)
  • TABLE 652 REVVITY: PRODUCTS/SERVICES OFFERED
  • TABLE 653 REVVITY: DEALS
  • 15.1.8 CHARLES RIVER LABORATORIES
  • TABLE 654 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
  • FIGURE 47 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023)
  • TABLE 655 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED
  • TABLE 656 CHARLES RIVER LABORATORIES: DEALS
  • 15.1.9 BIO-RAD LABORATORIES, INC.
  • TABLE 657 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • FIGURE 48 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
  • TABLE 658 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 659 BIO-RAD LABORATORIES, INC.: PRODUCT/SERVICE LAUNCHES
  • TABLE 660 BIO-RAD LABORATORIES, INC.: DEALS
  • 15.1.10 EUROFINS SCIENTIFIC
  • TABLE 661 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • FIGURE 49 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)
  • TABLE 662 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED
  • TABLE 663 EUROFINS SCIENTIFIC: DEALS
  • 15.1.11 BIOMERIEUX
  • TABLE 664 BIOMERIEUX: COMPANY OVERVIEW
  • FIGURE 50 BIOMERIEUX: COMPANY SNAPSHOT (2023)
  • TABLE 665 BIOMERIEUX: PRODUCTS/SERVICES OFFERED
  • TABLE 666 BIOMERIEUX: PRODUCT/SERVICE APPROVALS
  • TABLE 667 BIOMERIEUX: DEALS
  • 15.1.12 JSR CORPORATION
  • TABLE 668 JSR CORPORATION: COMPANY OVERVIEW
  • FIGURE 51 JSR CORPORATION: COMPANY SNAPSHOT (2023)
  • TABLE 669 JSR CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 670 JSR CORPORATION: DEALS
  • 15.1.13 LABORATORY CORPORATION OF AMERICA HOLDINGS
  • TABLE 671 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
  • FIGURE 52 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2023)
  • TABLE 672 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES OFFERED
  • TABLE 673 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT/SERVICE LAUNCHES
  • TABLE 674 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS
  • 15.1.14 EKF DIAGNOSTICS
  • TABLE 675 EKF DIAGNOSTICS: COMPANY OVERVIEW
  • FIGURE 53 EKF DIAGNOSTICS: COMPANY SNAPSHOT (2022)
  • TABLE 676 EKF DIAGNOSTICS: PRODUCTS/SERVICES OFFERED
  • 15.1.15 QUANTERIX
  • TABLE 677 QUANTERIX: COMPANY OVERVIEW
  • FIGURE 54 QUANTERIX: COMPANY SNAPSHOT (2023)
  • TABLE 678 QUANTERIX: PRODUCTS/SERVICES OFFERED
  • TABLE 679 QUANTERIX: PRODUCT LAUNCHES
  • TABLE 680 QUANTERIX: DEALS
  • 15.1.16 MESO SCALE DIAGNOSTICS, LLC.
  • TABLE 681 MESO SCALE DIAGNOSTICS, LLC.: COMPANY OVERVIEW
  • TABLE 682 MESO SCALE DIAGNOSTICS, LLC.: PRODUCTS/SERVICES OFFERED
• 15.2 OTHER PLAYERS
  • 15.2.1 CELERION
  • TABLE 683 CELERION: COMPANY OVERVIEW
  • 15.2.2 STANDARD BIOTOOLS
  • TABLE 684 STANDARD BIOTOOLS: COMPANY OVERVIEW
  • 15.2.3 SEBIA
  • TABLE 685 SEBIA: COMPANY OVERVIEW
  • 15.2.4 BIOAGILITIX LABS
  • TABLE 686 BIOAGILITIX LABS: COMPANY OVERVIEW
  • 15.2.5 STRESSMARQ BIOSCIENCES INC.
  • TABLE 687 STRESSMARQ BIOSCIENCES INC.: BUSINESS OVERVIEW
  • 15.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC.
  • TABLE 688 NORTHEAST BIOANALYTICAL LABORATORIES LLC.: BUSINESS OVERVIEW
  • 15.2.7 SIGNOSIS, INC.
  • TABLE 689 SIGNOSIS, INC.: BUSINESS OVERVIEW
  • 15.2.8 SERIMMUNE
  • TABLE 690 SERIMMUNE: COMPANY OVERVIEW
  • 15.2.9 THERAINDX LIFESCIENCES PVT. LTD.
  • TABLE 691 THERAINDX LIFESCIENCES PVT. LTD.: COMPANY OVERVIEW
  • 15.2.10 SYNEXA LIFE SCIENCES BV
  • TABLE 692 SYNEXA LIFE SCIENCES BV: COMPANY OVERVIEW
  • 15.2.11 DIATECH PHARMACOGENETICS
  • TABLE 693 DIATECH PHARMACOGENETICS: COMPANY OVERVIEW
  • 15.2.12 SINGULEX, INC.
  • TABLE 694 SINGULEX, INC.: COMPANY OVERVIEW
  • 15.2.13 R-BIOPHARM AG
  • TABLE 695 R-BIOPHARM AG: COMPANY OVERVIEW
  • 15.2.14 PROTEOME SCIENCES
  • TABLE 696 PROTEOME SCIENCES: COMPANY OVERVIEW
• *Details on Business Overview, Products/Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS